ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells

BACKGROUND: Platinum drugs, including cisplatin, are a frontline therapeutic in ovarian cancer treatment and acquired resistance to these agents is a major contributor to ovarian cancer morbidity and mortality. In this study a novel glycosylation-dependent mechanism for cisplatin resistance is descr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Schultz, Matthew J, Swindall, Amanda F, Wright, John W, Sztul, Elizabeth S, Landen, Charles N, Bellis, Susan L
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3637436/
https://ncbi.nlm.nih.gov/pubmed/23578204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1757-2215-6-25
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars